Global Restless Legs Syndrome Market

Global Restless Legs Syndrome Market Insights Forecasts to 2035

• The Global Restless Legs Syndrome Market Size Was valued at USD 691.55 Million in 2024
• The Global Restless Legs Syndrome Market Size is Expected to Grow at a CAGR of around 5.44% from 2025 to 2035
• The Worldwide Restless Legs Syndrome Market Size is Expected to Reach USD 1238.20 Million by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

 

 

According to a research report published by Spherical Insights and Consulting, the global restless legs syndrome market size was worth around USD 691.55 Million in 2024 and is predicted to grow to around USD 1238.20 Million by 2035 with a compound annual growth rate (CAGR) of 5.44% from 2025 to 2035. The Global Restless Legs Syndrome market will create future business prospects through the development of non-dopaminergic treatment methods and through personalized digital health solutions and through increased diagnostic capabilities and public awareness and through telehealth services and through treatment expansion in developing regions.

 

Market Overview

The Global Restless Legs Syndrome (RLS) Market refers to the worldwide industry focused on the diagnosis, treatment, and management of restless legs syndrome, a neurological disorder that results in an uncontrollable impulse to move the legs during periods of rest and sleep. The market experiences continuous growth because neurological disorders occur more frequently and people increasingly understand sleep disorders and healthcare services become more available. The primary treatment options for the condition include pharmaceutical drugs that consist of dopaminergic agents and anticonvulsants and iron therapies. The creation of new technologies introduces wearable devices for sleep tracking and digital therapeutic solutions and AI diagnostic systems and non-dopaminergic medicines which have reduced side effect profiles. Telemedicine integration and personalized treatment approaches are further improving patient outcomes while emerging markets present strong growth potential due to expanding healthcare infrastructure and awareness initiatives.

 

Report Coverage

This research report categorizes the restless legs syndrome market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the restless legs syndrome market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the restless legs syndrome market. 

 

Driving Factors

The global restless legs syndrome market growth derives from four main forces which include rising rates of neurological and sleep disorders and increased patient awareness and improved diagnostic capabilities and better access to healthcare services. The market expansion occurs because of two factors which are the need for effective treatments and the growth of research funding. The company can develop new business opportunities through three areas which include digital health innovation and development of personalized treatment plans and production of non-dopaminergic medications and expansion into new markets with developing healthcare systems.

 

Restraining Factors

Key restraining factors in the Global Restless Legs Syndrome market include limited disease awareness, misdiagnosis, side effects of current treatments, high therapy costs, and inadequate reimbursement policies in some regions which prevent patients from accessing treatment and obstruct market expansion.

 

Market Segmentation

The restless legs syndrome market share is classified into type and therapy type

• The primary restless legs syndrome segment dominated the market in 2024, approximately 60% and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the restless legs syndrome market is divided into primary restless legs syndrome and secondary restless legs syndrome. Among these, the primary restless legs syndrome segment dominated the market in 2024, approximately 60% and is projected to grow at a substantial CAGR during the forecast period. The condition requires continuous treatment because it affects more people and it has an unknown cause and it lasts throughout the patient's life. The segment experiences growth because patients become more aware of their condition and doctors can diagnose it earlier and patients need to take medication for extended periods. The company strengthens its market presence through research expansion on genetic connections and better treatment options. The market area remains restricted because secondary cases occur at lower rates and the condition requires specific treatment.

 

 

• The electronic segment accounted for the largest share in 2024, approximately 70% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the therapy type, the restless legs syndrome market is divided into pharmacological therapies and non-pharmacological therapies. Among these, the pharmacological therapies segment accounted for the largest share in 2024, approximately 70% and is anticipated to grow at a significant CAGR during the forecast period. The evidence from clinical studies shows that the treatments provide effective relief from symptoms while they help manage various medical conditions. Physicians prefer to use dopaminergic agents and anticonvulsants and iron supplements because these treatments have received established medical guidelines and they remain widely accessible. The increasing number of diagnosed cases together with the need for quick symptom relief leads to higher product consumption. The ongoing research for new drugs together with better drug formulations allows this business segment to maintain its dominant position in the market.

 

Regional Segment Analysis of the Restless Legs Syndrome Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the restless legs syndrome market over the predicted timeframe.

North America is anticipated to hold the largest share of the restless legs syndrome market over the predicted timeframe. The advanced healthcare infrastructure together with high public awareness about neurological and sleep disorders and strong diagnostic capabilities create a favorable medical environment. The combination of favorable reimbursement policies and widespread specialist access and strong pharmaceutical research capabilities enables treatment implementation. The region maintains its market leadership through the presence of top biotech companies combined with the quick adoption of new treatment methods.

 

Asia-Pacific is expected to grow at a rapid CAGR in the restless legs syndrome market during the forecast period. The need for healthcare services is increasing because of two factors first the growth of healthcare facilities second the rising number of neurological disorders which require testing and treatment. The demand for sleep disorder treatment increases because of three factors first rising healthcare expenses second increased public knowledge about sleep disorders third the existence of extensive untreated patient groups. The combination of government health programs with the international expansion of pharmaceutical companies in the region drives its accelerated development.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the restless legs syndrome market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• GlaxoSmithKline plc.
• Ligand Pharmaceuticals Incorporated
• Jazz Pharmaceuticals, Inc.
• Hisamitsu Pharmaceutical Co., Inc.
• Intas Pharmaceuticals Ltd
• Serina Therapeutics
• Apotex Inc
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Glenmark Pharmaceuticals Ltd
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• November 2023, Varco Leg Care, a consumer health-tech company, raised a bridge funding round of INR 2 Crore (USD 0.24 million) in the funding round led by the former CEO of Hindustan Coca-Cola, a blend of existing and new investors to advance its mission of revolutionizing leg care across India and the world. The company planned to expand its product portfolio with the introduction of unique topical phyto products for restless legs syndrome.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the restless legs syndrome market based on the below-mentioned segments: 

 

Global Restless Legs Syndrome Market, By Type

• Primary Restless Legs Syndrome
• Secondary Restless Legs Syndrome

 

Global Restless Legs Syndrome Market, By Therapy Type

• Pharmacological Therapies
• Non-pharmacological Therapies

 

Global Restless Legs Syndrome Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is driving growth in the Global Restless Legs Syndrome Market?

A: Rising neurological and sleep disorder prevalence, improved diagnostic capabilities, stronger patient awareness, expanding healthcare access, and increasing research funding are major drivers, alongside opportunities in digital health innovation, personalized therapies, and non-dopaminergic drug development.

 

2. Which segment dominates the market by type and why?

A: Primary restless legs syndrome leads due to higher prevalence, lifelong disease duration, continuous treatment demand, earlier diagnosis, and expanding genetic research, while secondary cases remain limited and condition-specific, restricting their overall market contribution.

 

3. Why do pharmacological therapies hold the largest therapy share?

A: Pharmacological treatments dominate because of proven clinical effectiveness, physician preference, established guidelines, wide availability of dopaminergic agents, anticonvulsants, and iron therapies, plus increasing diagnosis rates requiring rapid and sustained symptom relief.

 

4. Why does North America lead the global market?

A: Advanced healthcare infrastructure, strong awareness of neurological and sleep disorders, favorable reimbursement systems, robust pharmaceutical research, specialist accessibility, and early adoption of innovative treatments position North America as the largest regional market.

 

5. Why is Asia-Pacific the fastest-growing regional market?

A: Asia-Pacific grows rapidly due to expanding healthcare infrastructure, rising neurological disorder cases, increasing healthcare spending, improving diagnostic access, large untreated populations, supportive government initiatives, and expansion strategies of multinational pharmaceutical companies.